Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

Launched by FUDAN UNIVERSITY ·

Keywords

ClinConnect Summary

This clinical trial is studying two different treatment approaches for people with a type of rectal cancer called microsatellite stable (MSS) locally advanced rectal cancer. The goal is to see which treatment works better at completely getting rid of the cancer before surgery. One treatment involves a longer course of radiation combined with a chemotherapy drug called capecitabine. The other uses a shorter, more intense radiation schedule together with a combination of chemotherapy drugs (capecitabine and oxaliplatin), a type of medicine that helps the immune system fight cancer (called a PD-1 inhibitor), and an anti-inflammatory drug (a COX-2 inhibitor). Researchers will also look at how well these treatments help preserve the anus and how patients do over three years.

People who might be eligible for this study are adults with this specific type of rectal cancer. While the age range listed is wide, the study is open to all genders. If you join the trial, you will be randomly assigned to receive one of the two treatment plans. The study is currently recruiting participants, and it aims to better understand how adding immune and anti-inflammatory drugs can improve cancer treatment. This trial is important because it could lead to more effective treatments that help avoid surgery or improve long-term outcomes.

Gender

ALL

Eligibility criteria